The averages do obscure some nuance, Bonnet said
78-LB: Efficacy and Safety of Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Compared With Insulin Degludec in Patients With Type 2 Diabetes (SURPASS-3)
For example, studies on semaglutide 2.4 mg daily reveal an average 8% weight loss in individuals with diabetes over 60 weeks, while those without diabetes see closer to 11%
You can choose exactly how many of which flavors you want, which is a nice bonus
The Foundation: Why GLP-1 Agonism Generated So Much Research Interest The story starts with one hormone pathway
This includes adopting a balanced diet, increasing physical activity, and maintaining regular medical follow-ups